Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage

Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: To investigate the multi-biomarker disease activity (MBDA) score by comparison with imaging findings in an investigator-initiated rheumatoid arthritis (RA) trial (HURRAH trial, NCT00696059).

METHOD: Fifty-two patients with established RA initiated adalimumab treatment and had magnetic resonance imaging (MRI), ultrasonography (US), computed tomography (CT), and radiography performed at weeks 0, 26, and 52. Serum samples were analysed using MBDA score assays and associations between clinical measures, MBDA score, and imaging findings were investigated.

RESULTS: The MBDA score correlated significantly with MRI synovitis (rho = 0.65, p < 0.001), MRI bone marrow oedema (rho = 0.36, p = 0.044), and US power Doppler (PD) score at week 26 (rho = 0.35, p = 0.039) but not at week 0 or week 52. In the 15 patients who had achieved a Disease Activity Score based on C-reactive protein (DAS28-CRP) < 2.6 at week 26, MRI and/or US detected subclinical inflammation and 13 (87%) had a moderate/high MBDA score. For the cohort with available data, none of the four patients in MBDA remission (score ≤ 25) at week 26 had progression of imaging damage from baseline to week 52 whereas progression was observed in three out of nine (33%) and seven out of 21 (33%) patients with moderate (30-44) and high (> 44) MBDA scores, respectively.

CONCLUSIONS: In this cohort, the MBDA score correlated poorly with MRI/US inflammation. However, the MBDA score and MRI/US were generally concordant in showing signs of inflammation in most patients in clinical remission during anti-tumour necrosis factor (anti-TNF) therapy. MBDA scores were elevated in all patients with structural damage progression.

Original languageEnglish
JournalScandinavian Journal of Rheumatology
Volume46
Issue number5
Pages (from-to)353-358
Number of pages6
ISSN0300-9742
DOIs
Publication statusPublished - Sep 2017

Bibliographical note

COPECARE

    Research areas

  • Adalimumab, Aged, Antirheumatic Agents, Arthritis, Rheumatoid, Biomarkers, C-Reactive Protein, Denmark, Disease Progression, Female, Humans, Joints, Magnetic Resonance Imaging, Male, Methotrexate, Middle Aged, Patient Acuity, Radiography, Remission Induction, Research Design, Statistics as Topic, Synovitis, Tomography, X-Ray Computed, Tumor Necrosis Factor-alpha, Ultrasonography, Journal Article

ID: 52411682